Market Synopsis:

Diabetic Retinopathy Market Research Report - Global Forecast till 2025,Market Research Future (MRFR)’s study reveals that the global diabetic retinopathy market is anticipated to expand at a CAGR of 5.2% during the forecast period 2017 to 2023. The rising burden of diabetes is prognosticated to emerge as the driving force of market growth. In addition, rising awareness about the disease has intensified the need for advanced diagnostic tests for early diagnosis. This, in turn, is forecasted to accelerate the revenue creation for the market participants.

Market Segmentation:

By type, the global diabetic retinopathy market has been segmented into non-proliferative diabetic retinopathy and proliferative advanced diabetic retinopathy.

By diagnosis, the diabetic retinopathy market has been segmented into fluorescein angiography and optical coherence tomography.

By treatment, the global diabetic retinopathy market has been segmented into laser treatment, anti-VEGF Therapy, vitrectomy, and others. The laser treatment is sub-segmented into focal laser treatment and scatter laser treatment.

By end-user, the diabetic retinopathy market has been segmented into hospitals and clinics, diagnostic centers, research institutes, and others.

Competitive Dashboard:

Some of the key players profiled in the report are Novartis AG (Germany), Regeneron Pharmaceuticals Inc. (U.S.), Kowa Group (Japan), Bayer (Germany), ThromboGenics (U.S.), Sirnaomics (U.S.), Glycadia Pharmaceuticals (U.S.), Actavis Plc (U.K.), Ampio Pharmaceuticals (U.S.), Genentech (U.S.), Alimera Sciences (U.S.), and BCN Peptides (Spain).

Global Diabetic Retinopathy Market Research Report: Information by Type (Non-proliferative and Proliferative), Treatment (Anti-VEGF Drugs, Laser Photocoagulation, Vitreoretinal Surgery, Steroid Injection), by End User (Hospitals, Ambulatory Surgical Centers, Others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2025 : https://www.marketresearchfuture.com/reports/diabetic-retinopathy-market-5792